<DOC>
	<DOCNO>NCT00054496</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth cancer cell block enzymes necessary cancer cell growth . PURPOSE : Phase II trial study effectiveness erlotinib treat patient recurrent progressive glioblastoma multiforme .</brief_summary>
	<brief_title>Erlotinib Treating Patients With Recurrent Progressive Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient recurrent progressive glioblastoma multiforme treat erlotinib . - Determine progression-free overall survival patient treated drug . OUTLINE : Patients receive oral erlotinib daily . Treatment continue absence disease progression unacceptable toxicity . Patients follow survival . PROJECTED ACCRUAL : A total 73 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm glioblastoma multiforme Radiographic evidence recurrence progression Biopsies confirm tumor recurrence allow sufficent percentage case confirm recurrent tumor Previously treat optimal radiotherapy least 1 cytotoxic chemotherapy regimen PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 2 time normal Alkaline phosphatase great 2 time normal ALT great 3 time normal Renal BUN great 1.5 time normal OR Creatinine great 1.5 time normal Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No medical condition would interfere oral administration erlotinib No medical psychiatric illness would preclude study therapy No active infection No malignancy within past 3 year except surgically cure carcinoma situ cervix nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy brain cancer No concurrent biologic therapy brain cancer Chemotherapy See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) recover No concurrent chemotherapy brain cancer Endocrine therapy Concurrent glucocorticosteroids allow No concurrent hormonal therapy brain cancer Radiotherapy See Disease Characteristics Surgery Not specify Other No prior epidermal growth factor receptor ( EGFR ) inhibitor No concurrent EGFR inhibitor No concurrent antineoplastic therapy No concurrent antiepileptic agent modest nonenzymeinducing drug follow : Gabapentin Lamotrigine Divalproex Felbamate Levetiracetam Tiagabine Topiramate Zonisamide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>